GlassScriptPhysician profile
Bret A Witter
NPI 1396783387
$1,874.28
in general payments reported to CMS, 2019-2025
25 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $157 · 2021: $401 · 2022: $237 · 2023: $347 · 2024: $212 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $316.42 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $305.52 | 2019-2022 | |
| Atricure, INC. | $161.63 | 2019-2024 | |
| Boston Scientific Corporation | $161.29 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $160.00 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $107.82 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.48 | 2023-2025 | Lifevest |
| Irhythm Technologies, INC. | $70.66 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $53.28 | 2022 | |
| Medtronic, INC. | $48.42 | 2022-2023 | Venaseal |
| Sanofi-Aventis U.S. LLC | $45.63 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $44.38 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.31 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $37.14 | 2021 | |
| Resmed Corp | $30.02 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $26.76 | 2025 | |
| Abiomed | $24.71 | 2025 | |
| Altathera Pharmaceuticals LLC | $24.24 | 2025 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals, LTD. | $23.44 | 2021 | |
| Lundbeck LLC | $20.35 | 2019 | |
| Astellas Pharma US INC | $19.63 | 2021 | |
| Amarin Pharma, INC. | $15.71 | 2020 | |
| Impulse Dynamics (USA) INC. | $15.26 | 2023 | Optimizer |
| Bardy Diagnostics, INC. | $14.91 | 2022 | |
| Celgene Corporation | $14.27 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Witter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.